Business Wire

PA-PPG

Share
PPG sets science-based 2030 decarbonization targets, reports 2022 sustainability progress

PPG (NYSE:PPG) today announced its near-term 2030 sustainability goals, including greenhouse gas (GHG) emissions targets that have been validated by the Science Based Targets initiative (SBTi). The company also marked strong progress against its environmental, social and governance (ESG) priorities, reporting increased sales of sustainably advantaged products, more efficient operations, strong momentum towards achieving diversity, equity and inclusion goals, greater supplier sustainability and strengthened support within communities where the company operates.

“PPG has long been committed to reducing the environmental impact of its own operations, and we are proud to have validated science-based GHG emissions targets that are in line with the expectations of the Paris Agreement,” said Diane Kappas, PPG vice president, global sustainability. “By raising our sustainability ambitions and increasing sales of sustainable solutions for our customers, PPG is advancing its leadership in the paints and coatings industry.”

PPG has committed to reduce absolute emissions from its own operations (scope 1 and 2) by 50% by 2030 from a 2019 base year. It has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, processing of sold products, and end-of-life treatment of sold products by 30% within the same timeframe. The company’s emissions reduction strategy for its own operations includes energy efficiency projects and renewable energy sourcing. Within the value chain – or scope 3 – PPG is collaborating with suppliers to identify GHG emissions reduction opportunities and lower-carbon raw material sources. PPG recently signed an agreement with NRG Energy Inc. that will enable four PPG paints and coatings manufacturing facilities and 62 PPG PAINTS™ stores in Texas to operate on 100% renewable electricity.

In addition to its science-based emission targets, PPG’s other 2030 ESG targets against a 2019 baseline are:

  • 50% of sales from sustainably advantaged products
  • 15% reduction in water intensity at priority sites
  • 25% reduction in waste intensity
  • Reuse, recycle or recover 100% of process waste
  • $5 million additional COLORFUL COMMUNITIES® funding, with each project incorporating an element of sustainability, making the total investment $15 million since 2015
  • 100% of key suppliers assessed against sustainability and social responsibility criteria
  • 100% of employees go home safely each day
  • 5% annual reduction in spill and release rate

Furthermore, the company outlined key progress from the 2022 reporting year including:

  • Developing sustainable innovations that meet customers’ greatest needs, such as the launch of PPG INNOVEL® PRO, a non-bisphenol/non-BPA coating that ensures minimal spoilage and protection for aluminum beverage cans, while promoting circularity.
  • Collaborating with Steelcase, a U.S. manufacturer of architecture, furniture and technology products, to further increase the circularity of PPG powder coatings. PPG developed processes to recycle powder overspray into new coatings, which Steelcase uses on brackets, inside drawers and other less-visible surfaces in its products.
  • Continued investment in PPG’s signature Colorful Communities initiative. The company marked more than 470 projects, impacting more than 8 million people since 2015.
  • Strong improvement against 2025 diversity, equity and inclusion aspirational goals, including:
    • 19% increase in U.S. non-frontline Black headcount
    • 16% increase in U.S. non-frontline Latino headcount
    • 8% increase in U.S. non-frontline Asian headcount
    • 31% representation of non-frontline female professionals; a 180 basis-point improvement from 2021

“We remain committed to our journey of fostering a more diverse and inclusive community both within and beyond PPG,” said Marvin Mendoza, PPG global head, diversity, equity and inclusion. “We know that diverse teams perform better, and our 2022 progress is enabling a more equitable, inclusive future where employees feel even more empowered to bring their whole selves to work.”

Additional 2022 progress is outlined in further detail in PPG’s just-released 2022 Environmental, Social and Governance (ESG) Report at ppg.com/sustainability.

The Science Based Targets initiative (SBTi) mobilizes companies to set science-based targets and boost their competitive advantage in the transition to the low-carbon economy. It is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi call to action is one of the We Mean Business Coalition commitments. The initiative defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies’ targets.

PPG: WE PROTECT AND BEAUTIFY THE WORLD®

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

PPG Paints is a trademark and Colorful Communities, Innovel, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.

CATEGORY Sustainability

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005110/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye